Latest Hansa Biopharma News & Updates

See the latest news and media coverage for Hansa Biopharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Hansa Biopharma

Developer of immunomodulatory treatments for rare immunological diseases

hansabiopharma.com
Headquarters
Lund, Sweden
Founded year
2007
Company type
Public company
Number of employees
125–200
Industry
Pharmaceuticals

Last updated

Latest news about Hansa Biopharma

In short: Hansa Biopharma secured a December 2026 FDA action date for imlifidase and entered a €115 million licensing agreement with SERB.

Company announcements

Hansa Biopharma

Hansa Biopharma announces Q2 2026 interim results conference call

The report covers January-June 2026, and management will review results and provide business and pipeline update.

Unlock all announcements with a

Media coverage

BioStock

News roundup Friday August 21 - Biostock

Hansa Biopharma announces that a confidential draft registration document has been submitted to the US SEC to enable a potential listing of American depositary receipts in...

Financial Times

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment...

Unlock all articles with a

Never miss news about Hansa Biopharma

Track Hansa Biopharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Hansa Biopharma competitors & trending companies

Browse news for competitors to Hansa Biopharma and other trending companies.